November 18, 2026
Health news, explained with evidence
LIVE
Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine Understanding and Addressing Love Handles Through Lifestyle Changes Ciele Releases New Woolmark-Certified Merino Winter Running Apparel Preventive Services Task Force Resumes Meetings Under New Leadership Blood-Based Genetic Signature May Predict CAR T-Cell Therapy Success in Lymphoma Ultraprocessed Diets May Impact Brain Reward Systems in Younger Adults Addressing Body Image and the Reality of Gluteal Anatomy Migraine and Smoking Linked to Increased Early Stroke Risk in Women CBD Oil Found Ineffective for Managing Behavioral Issues in Youths with Intellectual Disabilities Expert Advice on Hydration Gear Sparks Debate Among Recreational Runners A Structured Approach to Beginning a Strength and Cardio Routine

Weekly Health Roundup: GLP-1 Safety, HIPAA Updates, and FDA Approvals

🧠 AI Analysis 2 min read 👁 0

Recent health reports highlight serious conditions linked to GLP-1 receptor agonists, updated HIPAA response timelines for providers, and new FDA approvals for home-use medications and insulin pumps.

Weekly Health Roundup: GLP-1 Safety, HIPAA Updates, and FDA Approvals🧠AI Analysis

Photo: medpagetoday.com

Key points

  • Washington Post examines rare GLP-1 side effects including gastroparesis and pancreatitis.
  • HHS mandates 15-day provider turnaround for HIPAA health data requests.
  • FDA approves new at-home agitation treatment and tubeless insulin pump.

A recent review by the Washington Post has brought attention to several rare but serious medical events linked to GLP-1 receptor agonists, including ischemic optic neuropathy, gastroparesis, thyroid C-cell tumors, gallstones, and pancreatitis. While these medications remain widely prescribed for weight management and diabetes, researchers continue to monitor their full safety profile. Patients and healthcare providers should carefully weigh potential risks, and anyone considering changes to their treatment plan should consult a physician.

In federal policy updates, the Department of Health and Human Services (HHS) finalized modifications to HIPAA regulations, which now mandate that medical providers fulfill health data requests within a 15-day window. Meanwhile, the FDA granted approval for Teva Pharmaceuticals' dexmedetomidine sublingual film (Igalmi) for at-home use in managing agitation related to schizophrenia, schizoaffective disorder, and bipolar disorders. Additionally, the agency cleared MiniMed's tubeless insulin pump (MiniMed Fit) for individuals aged 7 and older managing type 1 or type 2 diabetes.

Public health reporting also underscored shifting demographics in caregiving and maternal outcomes. A report from the National Center for Health Statistics indicated that nearly one in five surveyed adults acted as a caregiver in the past month, with female caregivers outnumbering males. Separately, a Texas report revealed that maternal mortality rates have returned to pre-pandemic levels, though mental health conditions emerged as a leading cause of mortality, and disparities persist for Black mothers.

  • GLP-1 Safety: Media reports spotlighted rare complications associated with the drug class, such as pancreatitis and gastroparesis.
  • Data Access: HHS updated HIPAA rules requiring providers to respond to medical data requests in 15 days.
  • Device Approvals: The FDA cleared a new tubeless insulin pump for patients aged 7 and older.

Source medpagetoday.com — medpagetoday.com/endocrinology/obesity/123913 ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.